Guide for patients & caregivers
Columnar Cell Change on a Breast Biopsy: What Does It Mean?
Columnar cell change on a breast biopsy explained: how it differs from flat epithelial atypia (FEA), B2 vs B3, and when excision or follow-up is discussed.
Prepared with AI assistance and checked against the cited sources. No independent clinician review has been completed. How we prepare articles
What does columnar cell change on a breast biopsy mean?
Columnar cell change means the pathologist saw cells lining small milk-producing units of the breast that are taller (column-shaped) than usual. Without atypia, it is a benign finding, usually placed in the B2 (benign) category. When the cells also look mildly unusual, the pathologist calls it flat epithelial atypia (FEA). FEA is still not cancer, but it is usually placed in the B3 group, which often leads to a discussion about removing the area or watching it with imaging.
This guide explains these report terms for adults who already have a breast biopsy result. It cannot interpret your own slides or images, and it does not predict what any further test will show. Your breast team holds the full picture.
When should I get checked sooner?
A columnar cell change result does not itself cause symptoms. A new change in the breast still needs checking, even soon after a benign biopsy. The NHS advises seeing a GP for a new lump or swelling in the breast, chest or armpit, or changes that are not normal for you.
After a biopsy, Breast Cancer Now says the breast may ache and be bruised for days or weeks. If you are worried about how the site is healing, contact the breast clinic that did the test.
- A new lump, or a lump that keeps growing, in the breast, chest or armpit.
- Skin dimpling, a change in skin colour, or a change in breast size or shape.
- Nipple discharge (when not pregnant or breastfeeding), especially if bloodstained, or a nipple that turns inwards or has a rash.
- A painful, warm or red breast. The NHS advises asking for an urgent GP appointment or using NHS 111 (or your local urgent service).
Is columnar cell change the same as flat epithelial atypia?
They belong to the same family, called columnar cell lesions, but they are reported differently. The 2023 International Consensus Conference on B3 lesions notes that the WHO classification separates columnar cell lesions without nuclear atypia, treated as B2, from FEA, which shows mild atypia and is treated as B3.
In FEA, one to several layers of mildly unusual cells line the small units of the breast. The consensus paper says FEA often sits in widened units with secretions and calcifications. It is often found alongside other low-grade changes such as atypical ductal hyperplasia (ADH) or lobular neoplasia.
Telling these apart is a judgement made by looking at the tissue under the microscope. A 2026 expert review notes that pathologists can disagree on several B3 lesions. Many laboratories therefore hold internal reviews of difficult cases, and a specialist opinion can be sought when doubt remains.
What do B2 and B3 mean on a breast biopsy?
In the UK and some other countries, core biopsy results are often given a B number. Breast Cancer Now describes B2 as benign (not cancer) and B3 as abnormal or uncertain but probably benign. It says more tests are usually needed for B3, B4 or B5 results, or when the findings of all the tests do not agree.
A B3 label describes uncertainty about the sample, not a cancer diagnosis. Your report may use different wording if your service does not use B codes, so ask how your result is classified.
Does columnar cell change increase breast cancer risk?
According to the 2023 consensus paper, a few studies found that columnar cell lesions without atypia were linked with a slightly higher (about 1.5-fold) risk of later invasive breast cancer. That link may not be separate from other changes seen alongside them. The same paper says the evidence on FEA is limited, and its risk of progressing appears very low compared with ADH and lobular neoplasia.
These figures come from groups of people. They cannot tell you your own risk. Ask your team whether your result changes your screening or follow-up, and why.
When is excision discussed for flat epithelial atypia?
A needle biopsy takes only small samples. With FEA, the worry is that a more significant change nearby, such as ductal carcinoma in situ (DCIS), was missed. The consensus paper reports wide variation between studies in how often removing the area finds something more serious, a finding called an upgrade. Major reviews gave estimates of about 1 to 8 percent.
The consensus panel's recommendations depend on the type of biopsy. If FEA is found on a standard core needle biopsy, the panel preferred removing the area, either by vacuum-assisted excision (VAE) or by surgery, depending on how the lesion looks and its size. If FEA is found on a vacuum-assisted biopsy and more than 90 percent of the target, such as the calcifications, has been removed, most panellists were comfortable with imaging follow-up instead.
Surgery is more often discussed when the pathology and imaging do not match, when there is a mass, or when calcifications remain after the biopsy. Breast Cancer Now describes VAE as a needle procedure done under local anaesthetic, guided by mammogram or ultrasound, which may avoid an operation under general anaesthetic.
What decides the plan for me?
The 2026 review says B3 lesions should be discussed by a multidisciplinary team (MDT) of radiologists, pathologists and surgeons. The team weighs the tissue findings, the imaging, your risk factors, any symptoms and your preferences. The consensus paper lists age, how the area looked on imaging, other risk factors, lesion size and calcifications as key points.
Whether the change was found through screening or because of a symptom also matters. The 2026 review notes that small areas of atypia found near a lump are often incidental or part of a larger change. The plan may therefore differ from someone whose FEA was found through screening calcifications.
Questions to ask your breast team
Bring the full pathology and imaging reports if you can, and write down the answers.
- Is my result columnar cell change without atypia, or flat epithelial atypia? Which B category was given?
- Was the biopsy a core needle biopsy or a vacuum-assisted biopsy, and how much of the target area was removed?
- Do the biopsy findings match what the mammogram or ultrasound showed?
- Were other changes seen alongside it, such as atypical hyperplasia?
- Has the MDT discussed my result? Was a second pathology opinion needed?
- If removal is advised, would vacuum excision or surgery be used, and why?
- If follow-up is advised, what imaging, when, and who will contact me?
- Does this change my routine screening?
How can comparing similar cases on SameCase help?
On SameCase, patients and verified doctors share de-identified cases. Reading how others with a columnar cell or FEA result described their biopsy type, imaging and follow-up can help you notice details to ask about, such as whether the calcifications were fully removed. Other people's cases can differ from yours in important ways. We do not diagnose, and nothing there replaces the advice of your own breast team.
Sources and further reading
- Elfgen C et al. Third International Consensus Conference on B3 lesions, Virchows Archiv 2023 (CC BY, PubMed Central)
- Rakha EA et al. Management of high-risk (B3) breast lesions in symptomatic practice, Virchows Archiv 2026 (CC BY, PubMed Central)
- Breast Cancer Now: Breast biopsy and B1 to B5 results
- Breast Cancer Now: Hyperplasia and atypical hyperplasia, including vacuum-assisted excision (reviewed October 2024)
- NHS: Symptoms of breast cancer in women (reviewed March 2024)
- NHS: Breast abscess and urgent advice for a painful, warm or red breast
For patients & caregivers
Share your case and learn from others
Learn from doctors and other people's cases to find a way forward with your health problem. New cases are public immediately. Don't add names or identifying details.